Disclaimer: All information on this section is of a general nature. Before making any investment decision, you should consult your adviser.
Investment Ideas - BARD1 Life Sciences (BD1) on track for 2019 commercialisation
Since listing on the ASX in June 2016, BD1 has set a strong foundation for commencing, in the December half of 2017, the key clinical validation studies on its lead product - the BARD1 Lung Cancer Test.